Therapeutic update in the treatment of disruptive disorder with emotional dysregulation in children and adolescents : review of the literature
Introduction Disruptive Mood Dysregulation Disorder (DMDD) is a new disorder that has been added to the category of mood disorders in the fifth Diagnostic and Statistical Manual of Mental Disorders to distinguish chronic non-periodic irritability from the periodic irritability of bipolar disorder....
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2023-03-01
|
| Series: | European Psychiatry |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933823015122/type/journal_article |
| _version_ | 1797616173559316480 |
|---|---|
| author | H. Belhadga Z. Elmaataoui H. Kisra |
| author_facet | H. Belhadga Z. Elmaataoui H. Kisra |
| author_sort | H. Belhadga |
| collection | DOAJ |
| description |
Introduction
Disruptive Mood Dysregulation Disorder (DMDD) is a new disorder that has been added to the category of mood disorders in the fifth Diagnostic and Statistical Manual of Mental Disorders to distinguish chronic non-periodic irritability from the periodic irritability of bipolar disorder. The main characteristic of DMDD is chronic and severe irritability. Because it is a new diagnostic entity, little research has been done on it and the literature on the subject is still expanding.
Objectives
The purpose of this review article is to gather information on new therapies for the treatment of this disorder in children and adolescents.
Methods
The studies related to the treatment of DMDD were collected and analyzed. This study retrieved related articles from PubMed, SpringerLink, ScienceDirect, NCBI, The American Journal of Psychiatry, and EBSCO. Use keywords “disruptive” AND “mood” AND “dysregulation” AND “disorder” OR “Treatment” AND “DMDD” OR “Drug” AND “mood” AND “disorder” OR “Treatment” AND “SMD” OR “Treatment” AND “BP” OR “Treatment” AND “ADHD” OR “Antidepressant” OR “Mental”AND “Stabilizer” OR “temper” AND “outburst” OR “aggressive” AND "antipsychotics.
Results
To date, no medication has been approved by the FDA to treat EDD. Because there are no treatment standards, drug therapy focuses on the primary symptoms of EDD, such as severe chronic irritability, temper tantrums, and comorbidities, such as ADHD. Currently, medications used by clinicians to treat patients with EDD include antidepressants (fluoxetine, sertraline, citalopram), stimulants (methylphenidate), anxiolytics mood stabilizers (sodium valproate) and antipsychotics (haloperidol, risperidone, aripiprazole in combination with methylphenidate in ADHD-EDD comorbidity), atomoxetine, guanfacine, and amantadine.
To date, no medication has been approved by the FDA to treat EDD. Because there are no treatment standards, drug therapy focuses on the primary symptoms of EDD, such as severe chronic irritability, temper tantrums, and comorbidities, such as ADHD. Currently, medications used by clinicians to treat patients with EDD include antidepressants (fluoxetine, sertraline, citalopram), stimulants (methylphenidate), anxiolytics mood stabilizers (sodium valproate) and antipsychotics (haloperidol, risperidone, aripiprazole in combination with methylphenidate in ADHD-EDD comorbidity), atomoxetine, guanfacine, and amantadine.
Conclusions
As a new diagnosis, treatment guidelines for DMDD are still unclear. Preliminary results from this study suggest that clinicians tend to prescribe a variety of psychotropic medications. This heterogeneity in treatment choices may reflect the fact that these patients are on a bridge between disruptive behavior disorders (including ADHD) and mood disorders. The relative merits or demerits of these treatment choices should be evaluated in further studies.
Disclosure of Interest
None Declared |
| first_indexed | 2024-03-11T07:37:35Z |
| format | Article |
| id | doaj.art-f6d03efce3ba47f2b605aa2b469386c3 |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:37:35Z |
| publishDate | 2023-03-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-f6d03efce3ba47f2b605aa2b469386c32023-11-17T05:09:25ZengCambridge University PressEuropean Psychiatry0924-93381778-35852023-03-0166S721S72210.1192/j.eurpsy.2023.1512Therapeutic update in the treatment of disruptive disorder with emotional dysregulation in children and adolescents : review of the literatureH. Belhadga0Z. Elmaataoui1H. Kisra2Hôpital psychiatrique universitaire arrazi de Sale, Hôpital psychiatrique universitaire arrazi de Sale, Sale, MoroccoHôpital psychiatrique universitaire arrazi de Sale, Hôpital psychiatrique universitaire arrazi de Sale, Sale, MoroccoHôpital psychiatrique universitaire arrazi de Sale, Hôpital psychiatrique universitaire arrazi de Sale, Sale, Morocco Introduction Disruptive Mood Dysregulation Disorder (DMDD) is a new disorder that has been added to the category of mood disorders in the fifth Diagnostic and Statistical Manual of Mental Disorders to distinguish chronic non-periodic irritability from the periodic irritability of bipolar disorder. The main characteristic of DMDD is chronic and severe irritability. Because it is a new diagnostic entity, little research has been done on it and the literature on the subject is still expanding. Objectives The purpose of this review article is to gather information on new therapies for the treatment of this disorder in children and adolescents. Methods The studies related to the treatment of DMDD were collected and analyzed. This study retrieved related articles from PubMed, SpringerLink, ScienceDirect, NCBI, The American Journal of Psychiatry, and EBSCO. Use keywords “disruptive” AND “mood” AND “dysregulation” AND “disorder” OR “Treatment” AND “DMDD” OR “Drug” AND “mood” AND “disorder” OR “Treatment” AND “SMD” OR “Treatment” AND “BP” OR “Treatment” AND “ADHD” OR “Antidepressant” OR “Mental”AND “Stabilizer” OR “temper” AND “outburst” OR “aggressive” AND "antipsychotics. Results To date, no medication has been approved by the FDA to treat EDD. Because there are no treatment standards, drug therapy focuses on the primary symptoms of EDD, such as severe chronic irritability, temper tantrums, and comorbidities, such as ADHD. Currently, medications used by clinicians to treat patients with EDD include antidepressants (fluoxetine, sertraline, citalopram), stimulants (methylphenidate), anxiolytics mood stabilizers (sodium valproate) and antipsychotics (haloperidol, risperidone, aripiprazole in combination with methylphenidate in ADHD-EDD comorbidity), atomoxetine, guanfacine, and amantadine. To date, no medication has been approved by the FDA to treat EDD. Because there are no treatment standards, drug therapy focuses on the primary symptoms of EDD, such as severe chronic irritability, temper tantrums, and comorbidities, such as ADHD. Currently, medications used by clinicians to treat patients with EDD include antidepressants (fluoxetine, sertraline, citalopram), stimulants (methylphenidate), anxiolytics mood stabilizers (sodium valproate) and antipsychotics (haloperidol, risperidone, aripiprazole in combination with methylphenidate in ADHD-EDD comorbidity), atomoxetine, guanfacine, and amantadine. Conclusions As a new diagnosis, treatment guidelines for DMDD are still unclear. Preliminary results from this study suggest that clinicians tend to prescribe a variety of psychotropic medications. This heterogeneity in treatment choices may reflect the fact that these patients are on a bridge between disruptive behavior disorders (including ADHD) and mood disorders. The relative merits or demerits of these treatment choices should be evaluated in further studies. Disclosure of Interest None Declaredhttps://www.cambridge.org/core/product/identifier/S0924933823015122/type/journal_article |
| spellingShingle | H. Belhadga Z. Elmaataoui H. Kisra Therapeutic update in the treatment of disruptive disorder with emotional dysregulation in children and adolescents : review of the literature European Psychiatry |
| title | Therapeutic update in the treatment of disruptive disorder with emotional dysregulation in children and adolescents : review of the literature |
| title_full | Therapeutic update in the treatment of disruptive disorder with emotional dysregulation in children and adolescents : review of the literature |
| title_fullStr | Therapeutic update in the treatment of disruptive disorder with emotional dysregulation in children and adolescents : review of the literature |
| title_full_unstemmed | Therapeutic update in the treatment of disruptive disorder with emotional dysregulation in children and adolescents : review of the literature |
| title_short | Therapeutic update in the treatment of disruptive disorder with emotional dysregulation in children and adolescents : review of the literature |
| title_sort | therapeutic update in the treatment of disruptive disorder with emotional dysregulation in children and adolescents review of the literature |
| url | https://www.cambridge.org/core/product/identifier/S0924933823015122/type/journal_article |
| work_keys_str_mv | AT hbelhadga therapeuticupdateinthetreatmentofdisruptivedisorderwithemotionaldysregulationinchildrenandadolescentsreviewoftheliterature AT zelmaataoui therapeuticupdateinthetreatmentofdisruptivedisorderwithemotionaldysregulationinchildrenandadolescentsreviewoftheliterature AT hkisra therapeuticupdateinthetreatmentofdisruptivedisorderwithemotionaldysregulationinchildrenandadolescentsreviewoftheliterature |